These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 12877791

  • 1. A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.
    Zhu J, Ye P.
    Chin Med J (Engl); 2003 Jun; 116(6):840-3. PubMed ID: 12877791
    [Abstract] [Full Text] [Related]

  • 2. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L, Szostak WB, Grzybowska B, Białobrzeska-Paluszkiewicz J, Wiśniewska B, Stolarska I.
    Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
    [Abstract] [Full Text] [Related]

  • 3. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 4. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S.
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of 12-week treatment with fenofibrate 300 mg in Thai dyslipidemic patients.
    Koanantakul B, Jeamanukulkit N, Piamsomboon C, Chawantanpipat C, Khanacharoen I.
    J Med Assoc Thai; 2004 Nov; 87(11):1281-5. PubMed ID: 15825700
    [Abstract] [Full Text] [Related]

  • 6. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
    Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K.
    Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
    [Abstract] [Full Text] [Related]

  • 7. A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate.
    Levin A, Duncan L, Djurdjev O, Shapiro RJ, Frohlich J, Belanger A, Dumas R, Ross S.
    Clin Nephrol; 2000 Feb; 53(2):140-6. PubMed ID: 10711416
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
    Maciejewski S, Hilleman D.
    Pharmacotherapy; 2008 May; 28(5):570-5. PubMed ID: 18447655
    [Abstract] [Full Text] [Related]

  • 9. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.
    Wu TJ, Ou HY, Chou CW, Hsiao SH, Lin CY, Kao PC.
    Ann Clin Lab Sci; 2007 May; 37(2):158-66. PubMed ID: 17522372
    [Abstract] [Full Text] [Related]

  • 10. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
    Winkler K, Weltzien P, Friedrich I, Schmitz H, Nickell HH, Hauck P, Hoffmann MM, Baumstark MW, Wieland H, März W.
    Exp Clin Endocrinol Diabetes; 2004 May; 112(5):241-7. PubMed ID: 15146369
    [Abstract] [Full Text] [Related]

  • 11. [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia].
    Ceska R, Sobra J, Kvasnicka J, Procházková R, Kvasilová M, Haas T.
    Cas Lek Cesk; 1996 Jul 26; 135(13):413-6. PubMed ID: 8925538
    [Abstract] [Full Text] [Related]

  • 12. [Pleiotropic effect of the micronized fenofibrate: the reduction of plasma chlamydia pneumoniae antibody levels in patients with coronary artery disease].
    Márk L, Márki-Zay J, Orosz I, Kondacs A, Erdei F, Katona A.
    Orv Hetil; 2003 Apr 20; 144(16):765-8. PubMed ID: 12778627
    [Abstract] [Full Text] [Related]

  • 13. [Pleiotropic effects of micronized fenofibrate in patients with combined hyperlipidemia].
    Okopień B, Cwalina Ł, Haberka M, Kowalski J, Zieliński M, Szwed Z, Kalina Z, Herman ZS.
    Pol Merkur Lekarski; 2002 Dec 20; 13(78):465-9. PubMed ID: 12666442
    [Abstract] [Full Text] [Related]

  • 14. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
    Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Cariolou M, Ganotakis ES, Mikhailidis DP, Elisaf MS.
    J Cardiovasc Pharmacol Ther; 2006 Sep 20; 11(3):211-21. PubMed ID: 17056835
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.
    Farnier M, Freeman MW, Macdonell G, Perevozskaya I, Davies MJ, Mitchel YB, Gumbiner B, Ezetimibe Study Group.
    Eur Heart J; 2005 May 20; 26(9):897-905. PubMed ID: 15781429
    [Abstract] [Full Text] [Related]

  • 16. [Effect of micronized fenofibrate (lipantyl-200M) on synthesis of cholesterol in peripheral blood lymphocytes of patients with ischemic heart disease and hyperlipidemia].
    Ivanova TN, Poliakova ED, Olfer'ev AM, Perova NV.
    Biull Eksp Biol Med; 1998 May 20; 125(5):569-73. PubMed ID: 9644562
    [No Abstract] [Full Text] [Related]

  • 17. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
    Rouffy J, Sauvanet JP, Chanu B, Bakir R, Goy-Loeper J, Saya C, Pinaroli F.
    Nouv Presse Med; 1980 Dec 22; 9(49):3747-51. PubMed ID: 7208341
    [Abstract] [Full Text] [Related]

  • 18. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
    Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P, Fraioli A, Mastrantoni M, Maddaloni M, Letizia C.
    Metabolism; 2007 Nov 22; 56(11):1534-41. PubMed ID: 17950105
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH, Bays H, Rhyne J, Stein E, Rotenberg K, Doyle R.
    Clin Ther; 2005 Jun 22; 27(6):715-27. PubMed ID: 16117978
    [Abstract] [Full Text] [Related]

  • 20. [level of 7alpha-hydroxycholesterol in blood plasma as an indicator of cholesterol catabolism in hyperlipidemia and with hypolipidemic therapy].
    Poliakova ED, Ivanova TN, Voshchinnikov EI, Olfer'ev AM, Perova NV.
    Vopr Med Khim; 2000 Jun 22; 46(2):168-75. PubMed ID: 10885038
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.